Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces the dosing of the first patient in its Phase 2b clinical […]
Dogwood Therapeutics (Nasdaq: DWTX) announced the dosing of the first patient in its Phase 2b HALT-CINP trial evaluating Halneuron® for chemotherapy-induced neuropathic pain (CINP). Halneuron®, a NaV1.7 sodium channel inhibitor, previously demonstrated pain reduction in clinical trials. The company aims to enroll 100 patients by Q4 2025 for an interim analysis to inform the adaptive trial design. Dogwood is also developing IMC-1 for Fibromyalgia and IMC-2 for Long Covid fatigue.
